The Alzheimer's Disease Center (ADC) at New York University Langone Medical Center (NYULMC) is an Alzheimer's Disease Core Center (ADCC) that provides outstanding infrastructure, environment and core resources promoting cutting-edge research by bringing together clinical, translational, basic and psychosocial investigators to study the etiology, pathogenesis, diagnosis, treatment and prevention of Alzheimer's disease and related disorders (collectively referred to as AD). Now entering its 25th year, the NYU ADC continues to provide a mechanism for fostering and coordinating the interdisciplinary cooperation of a group of established investigators conducting programs of research on AD while providing a supportive milieu for early-stage investigators. The ADC supports innovative research by maintaining an integrated array of core facilities, including Administrative, Clinical, Neuropathology, Data Management and Statistical, Outreach, Recruitment and Education, and Neuroimaging and Psychosocial Cores. The principal goal of the ADC is to enhance the performance of innovative AD research, including research that may lead to potential disease-modifying therapies. Along with the overall NIA-ADC program, the NYU ADC has moved into a new era, capitalizing on the extraordinary opportunities presented by leveraging the strengths of the network of centers to provide large numbers of samples and standardized clinical, cognitive and biomarker data from well-characterized participants, as well as a large pool of potential participants for future AD-related research. At the same time, we place a strong emphasis on the unique contributions and new directions of the NYU ADC. Additionally, emphasis is placed on possibilities for utilizing the resources within our ADC and across the ADCs to advance and augment drug discovery and drug development for novel therapeutics for AD. Since its inception in 1990, the NYU ADC has facilitated cutting edge research defining normal aging and the transition to the earliest detectable stages of mild cognitive impairment (MCI) and AD. This longstanding research direction will continue to be our main scientific theme, with a particular focus over the past 15 years on better understanding the preclinical stages that precede MCI and mild AD. Thus, we will continue our scientific focus on elucidating the transition from normal aging to the earliest, preclinical stages of AD. Our collective research efforts investigating the clinical-pathological changes associated with cognitive impairment and the role of co-morbid pathologies and chronic conditions position us well to develop, test and validate novel strategies to address symptomatic, disease-modifying, and preventive therapeutic approaches being developed at our ADC and other ADCs.

Public Health Relevance

Now entering its 25th year, the New York University (NYU) Alzheimer's Disease Center (ADC) continues to foster and coordinate interdisciplinary research on Alzheimer's disease (AD) by providing investigators with shared core resources. The principal scientific goal is to enhance the performance of innovative research on the transition from normal aging to very early AD, and to translate this knowledge into the development of disease-modifying therapies that may lead to AD prevention.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Goñi, Fernando; Martá-Ariza, Mitchell; Herline, Krystal et al. (2018) Anti-?-sheet conformation monoclonal antibody reduces tau and A? oligomer pathology in an Alzheimer's disease model. Alzheimers Res Ther 10:10
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Wenning, Gregor; Trojanowski, John Q; Kaufmann, Horacio et al. (2018) Is multiple system atrophy an infectious disease? Ann Neurol 83:10-12

Showing the most recent 10 out of 604 publications